Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex322_11.htm |
| EX-32.1 - EX-32.1 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex321_8.htm |
| EX-31.2 - EX-31.2 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex312_9.htm |
| EX-31.1 - EX-31.1 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex311_13.htm |
| EX-21.1 - EX-21.1 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex211_12.htm |
| EX-10.31 - EX-10.31 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex1031_87.htm |
| EX-10.28 - EX-10.28 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex1028_50.htm |
| EX-10.22 - EX-10.22 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex1022_16.htm |
| EX-10.13 - EX-10.13 - TETRAPHASE PHARMACEUTICALS INC | ttph-ex1013_17.htm |
| 10-K - 10-K - TETRAPHASE PHARMACEUTICALS INC | ttph-10k_20171231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 No. 333-209991) pertaining to the 2013 Stock Incentive Plan and Inducement Stock Option Awards of Tetraphase Pharmaceuticals, Inc., |
|
|
(2) |
Registration Statement (Form S-8 No. 333-198098) pertaining to the 2014 Employee Stock Purchase Plan of Tetraphase Pharmaceuticals, Inc., |
|
|
(3) |
Registration Statement (Form S-8 No. 333-194125, No. 333-202576 and No. 333-216742) pertaining to the 2013 Stock Incentive Plan of Tetraphase Pharmaceuticals, Inc., |
|
|
(4) |
Registration Statement (Form S-8 No. 333-189361) pertaining to the 2006 Stock Incentive Plan and the 2013 Stock Incentive Plan of Tetraphase Pharmaceuticals, Inc., and |
|
|
(5) |
Registration Statement (Form S-3 No. 333-214500 and No. 333-222699) of Tetraphase Pharmaceuticals, Inc. |
of our reports dated March 6, 2018, with respect to the consolidated financial statements of Tetraphase Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Tetraphase Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Tetraphase Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 6, 2018